Contributions
Abstract: PB1959
Type: Publication Only
Background
Despite clinical and therapeutic advances on CML, little is known about its epidemiology and there are not many publications showing results on patients’ health in real life. Population registries allow to obtain information on incidence, prevalence and effectiveness of treatments; this information is usually obtained through clinical trials characterized by their strict inclusion and exclusion criteria.
Aims
To describe the epidemiological characteristics of patients with CML CP in Andalusia and to calculate the rates of incidence among patients older than 20, adjusted to the European population in order to allow for comparison with other registries.
Methods
Population-based retrospective descriptive study on real life, which analyzes the epidemiological features among patients included in RALMC since January 2002 to December 2016.
In order to calculate the accumulated incidence new diagnostics were taken since January 2005 until December 2012 and in order to compare with other incidence rates, adjustments via direct rates adjustment was made, taking as reference the standard a European population sample from IARC.
RALMC and its associated projects are carried out according to current Spanish legislation as well as recommendations for research projects given in the Helsinki Declaration.
Results
With a number of new diagnostics at 288 patients older than 20 in Andalusia between 2005 and 2012, accumulated incidence rates as it is adjusted to the European standard population for CML in Andalusia is of 0.97 cases out of every 100.000 inhabitants/year.
Until December 2016, 505 patients have been included, 279 males (55.2%). Mean age is 55 (20-90). 104 patients (20.6%) older than 70 with a mean of global follow-up of 86 months (11-194). 275 patients (54.5%) low-risk Sokal, 166 (32.9%) intermediate risk and 63 (12.5%) high risk. Low Hasford Euro score 248 patients (49.1%), intermediate 184 (36.4%), high 54 (10.7%) and 19 unknown (3.8%) and low EUTOS score in 383 patients (75.8%), high 103 (20.4%) and 19 unknown (3.8%).
BASELINE CHARACTERISTICS OF THE STUDY RALMC POPULATION (N=505 PATIENTS) | ||||||||||||||||
| Sex | Age | Sokal | Euro score | EUTOS | 1st line Treament | ||||||||||
M | Me | =>70 | L | I | H | L | I | H | Un | L | H | Un | Im | Nil | Das | |
n | 279 | 55 | 104 | 275 | 167 | 63 | 248 | 184 | 54 | 19 | 383 | 103 | 19 | 427 | 46 | 32 |
(%) | 55.2 |
| 20.6 | 54.5 | 33 | 12.5 | 49.1 | 34.6 | 10.7 | 3.8 | 75.8 | 20.4 | 3.8 | 84.6 | 9.1 | 6.3 |
Conclusion
CML incidence in Andalusia is comparable to that described in the scientific literature and is in keeping with results from the European registry EUTOS from 2015.
Epidemiological characteristics from our patients are homogeneous to those described in other registries in terms of sex, age of diagnosis and prognostication indices distribution.
The creation of RALMC on population basis allows to obtain information regarding CML in real life, which is in turn needed for health planning and resource management in clinical praxis and support outside of clinical trials. However, methodological limitations in our registry must be taken into consideration: in Spain, CML patients are not obliged to declare their status, participation in RALMC is voluntary and inclusion is done under written consent.
Session topic: 8. Chronic myeloid leukemia - Clinical
Keyword(s): Chronic myeloid leukemia, epidemiology
Abstract: PB1959
Type: Publication Only
Background
Despite clinical and therapeutic advances on CML, little is known about its epidemiology and there are not many publications showing results on patients’ health in real life. Population registries allow to obtain information on incidence, prevalence and effectiveness of treatments; this information is usually obtained through clinical trials characterized by their strict inclusion and exclusion criteria.
Aims
To describe the epidemiological characteristics of patients with CML CP in Andalusia and to calculate the rates of incidence among patients older than 20, adjusted to the European population in order to allow for comparison with other registries.
Methods
Population-based retrospective descriptive study on real life, which analyzes the epidemiological features among patients included in RALMC since January 2002 to December 2016.
In order to calculate the accumulated incidence new diagnostics were taken since January 2005 until December 2012 and in order to compare with other incidence rates, adjustments via direct rates adjustment was made, taking as reference the standard a European population sample from IARC.
RALMC and its associated projects are carried out according to current Spanish legislation as well as recommendations for research projects given in the Helsinki Declaration.
Results
With a number of new diagnostics at 288 patients older than 20 in Andalusia between 2005 and 2012, accumulated incidence rates as it is adjusted to the European standard population for CML in Andalusia is of 0.97 cases out of every 100.000 inhabitants/year.
Until December 2016, 505 patients have been included, 279 males (55.2%). Mean age is 55 (20-90). 104 patients (20.6%) older than 70 with a mean of global follow-up of 86 months (11-194). 275 patients (54.5%) low-risk Sokal, 166 (32.9%) intermediate risk and 63 (12.5%) high risk. Low Hasford Euro score 248 patients (49.1%), intermediate 184 (36.4%), high 54 (10.7%) and 19 unknown (3.8%) and low EUTOS score in 383 patients (75.8%), high 103 (20.4%) and 19 unknown (3.8%).
BASELINE CHARACTERISTICS OF THE STUDY RALMC POPULATION (N=505 PATIENTS) | ||||||||||||||||
| Sex | Age | Sokal | Euro score | EUTOS | 1st line Treament | ||||||||||
M | Me | =>70 | L | I | H | L | I | H | Un | L | H | Un | Im | Nil | Das | |
n | 279 | 55 | 104 | 275 | 167 | 63 | 248 | 184 | 54 | 19 | 383 | 103 | 19 | 427 | 46 | 32 |
(%) | 55.2 |
| 20.6 | 54.5 | 33 | 12.5 | 49.1 | 34.6 | 10.7 | 3.8 | 75.8 | 20.4 | 3.8 | 84.6 | 9.1 | 6.3 |
Conclusion
CML incidence in Andalusia is comparable to that described in the scientific literature and is in keeping with results from the European registry EUTOS from 2015.
Epidemiological characteristics from our patients are homogeneous to those described in other registries in terms of sex, age of diagnosis and prognostication indices distribution.
The creation of RALMC on population basis allows to obtain information regarding CML in real life, which is in turn needed for health planning and resource management in clinical praxis and support outside of clinical trials. However, methodological limitations in our registry must be taken into consideration: in Spain, CML patients are not obliged to declare their status, participation in RALMC is voluntary and inclusion is done under written consent.
Session topic: 8. Chronic myeloid leukemia - Clinical
Keyword(s): Chronic myeloid leukemia, epidemiology